Cooperative research for new Hope

Cooperative research for new Hope


Our goal is to advance clinical research on rare diseases and to develop a therapy for previously untreatable lysosomal storage diseases (LSD). At the same time, we are committed to the health concerns of affected patients.
We do this by providing the scientific and medical community with insights into LSDs and by helping to develop innovative therapies. Our patients are valuable players and partners in this process. We work with a personal approach and in an atmosphere of trust.

SphinCS - Clinical Science for LSD | SphinCS - Clinical Science for LSD | Hochheim

For you as a patient

  • we offer the opportunity to participate in the latest drug trials.
  • we offer access to clinical trials and the latest scientific information.
  • we offer time and care.
  • we provide close cooperation with patient care facilities.
  • we promote your active role in clinical trials (patient reported outcome).

Current Studies

Clinical research for lysosomal diseases is fortunately receiving more and more attention. We would like to help you stay up to date and inform you accordingly about studies currently taking place.
An overview of the current therapy concepts with gene therapy, haematopoietic stem cell transplantation (bone marrow transplantation), enzyme replacement therapy, substrate reduction therapy and chaperone therapy is scientifically presented in the article "Precision Medicine for Lysosomal Disorders" (Jul 26 2020). Furthermore, we have tried to illustrate the topic of therapy concepts for lysosomal diseases in a comic.

SphinCS - Clinical Science for LSD | Current Studies

Lysosomal Storage Disorders

The Scorpion

Fabry Disease

Fabry Disease is an X-chromosomal inherited lysosomal storage disorder based on the deficiency of the enzyme alpha-galactosidase A. This leads to accumulation of globotriaosyl-ceramide (Gb3) in the cells of various organs. The clinical picture of M. Fabry is very heterogeneous and ranges from mild phenotypes rather in heterozygous women to severe clinical course in classically affected men. Characteristic symptoms include acroparesthesia, cardiac symptoms associated with cardiomyopathy and arrhythmias, progressive renal failure and cerebro-vascular complications (strokes). A typical eye manifestation is the cornea verticillata. Therapeutically, 3 drugs are currently available: enzyme replacement therapies with agalsidase alfa or agalsidase beta or chaperone therapy with migalastat. 

Fabry Disease | SphinCS - Clinical Science for LSD

What are Lysosomal Storage Disorders?

Lysosomal Storage Disorders (LSDs) are a group of more than 50 rare hereditary metabolic diseases. The diseases are characterized by an abnormal accumulation of various toxic substances in the body cells as a result of enzyme defects.

Lysosomal storage diseases affect the lysosome, a structure in the cells that breaks down substances such as proteins, carbohydrates and old cell parts so that the body can recycle them. As a result, various parts of the body may be affected, including the skeleton, brain, skin, heart and central nervous system. New lysosomal storage diseases continue to be identified.

SphinCS - Clinical Science for LSD | LSD

Looking forward to hear from you

By submitting the form, I agree that my data from the contact form will be collected and processed to answer my request. You can find further information in our data protection declaration.